FDA Backs Merck's Vytorin in Kidney Disease Patients

by Dr. Trupti Shirole on  November 1, 2011 at 3:26 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

The Food and Drug Administration (FDA) has stated that Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with chronic kidney disease (CKD). Vytorin is a combination of ezetimibe and simvastatin. Vytorin which had come under scrutiny in 2008 for potential cancer risks has no new safety concerns.
 FDA Backs Merck's Vytorin in Kidney Disease Patients
FDA Backs Merck's Vytorin in Kidney Disease Patients

Vytorin lowered heart related problems in kidney patients upto 16% as compared to placebo. These results were variable on whether the patients were on dialysis. Patients who received dialysis showed 6% reduction in heart problems as compared to 22% reduction for patients not on dialysis.

The FDA will ask members of the Endocrinologic and Metabolic Drugs Advisory Committee to comment on the disparity and to vote on the overall safety and efficacy of Vytorin for kidney disease patients on Wednesday.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Urinary Stones In Children Vesico-Ureteric Reflux Causing UTI in Children Hydronephrosis / Antenatal Counseling Kidney Disease Kidney Kidney Health Stones in Urinary Tract Renal Tubular Acidosis Diabetic Kidney Disease Kidney Biopsy 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive